Laboratory markers and clinical parameters of the cohort. (A) Clinical data of the enrolled patients: lymphoproliferation (P < .0001 definite vs unlikely ALPS) and multilineage cytopenia (P = .5168). (B) DNTs. (C) The in vitro apoptosis functional test. (D) The level of sFASL (P = .0674 definite vs suspected ALPS). (E) IL-10 (P = .0624 definite vs suspected and unlikely ALPS). (F) IL-18 (P = .0615 definite vs suspected and unlikely ALPS). (G) Assessment of the marker combination comparing the definite ALPS and unlikely ALPS groups. All data are presented as median ± interquartile range. *P = .0496 (suspected vs unlikely ALPS), **P = .0019 (definite vs suspected ALPS; panel C), **P = .0013 (definite vs unlikely ALPS; panel D), ****P < .0001 (definite vs suspected ALPS; panel B), ****P < .0001 (definite vs unlikely ALPS; panel C).